| Name | Piroxicam |
| Description | Piroxicam (CP-16171) is a non-specific COX inhibitor. |
| In vitro | Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. Piroxicam and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures. [1] |
| In vivo | Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. [2] Piroxicam increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. Piroxicam up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. [3] Piroxicam combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. [4] Piroxicam inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and Piroxicam does not have any direct cytotoxic effects in vitro. [5] Piroxicam also binds strongly to plasma proteins and Piroxicam could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. Piroxicam prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats. [6] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 1 mg/mL (3.02 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.04 mM), Sonication is recommended.
DMSO : 45 mg/mL (135.81 mM), Sonication is recommended.
|
| Keywords | Piroxicam | Inhibitor | inhibit | Cyclooxygenase | CP16171 | CP 16171 | COX |
| Inhibitors Related | Naproxen sodium | Acetaminophen | Phenidone | 4-Aminosalicylic acid | Gallic Acid Monohydrate | Diclofenac Potassium | Indomethacin | Paradol | Trometamol | 5-Methylfurfural | Phenylbutazone | Magnesium sulfate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
